Dalpiciclib combined with endocrine therapy significantly enhances progression-free survival in HR+/HER2– breast cancer, as shown in the DAWNA-A trial.

These health care professionals are crucial to optimizing safety in medication therapy, addressing policy barriers, and the collaboration with others…

Panelists discuss how pharmacists play a crucial role in biliary tract cancer management by leveraging their detailed medication knowledge to…

Panelists discuss how trastuzumab deruxtecan demonstrated a 22% overall response rate in patients with biliary tract cancer (56.3% in HER2…

Panelists discuss how HER2-targeted agents in biliary tract cancers include trastuzumab deruxtecan (an antibody-drug conjugate that acts like a “smart…

Panelists discuss how first-line treatment typically involves gemcitabine-based cytotoxic chemotherapy (particularly gemcitabine with cisplatin) that has evolved to include chemo-immunotherapy…

Panelists discuss how comprehensive next-generation sequencing is performed to identify key biomarkers including IDH1/2 mutations and FGFR2 fusions (predominantly in…

The long-term outcomes from the CARTITUDE-1 trial in multiple myeloma and durable complete response data from the STARGLO trial in…

States have expanded access to over-the-counter ivermectin, raising concerns among health experts about safety, misinformation, and self-medication risks.